Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case

Creative Commons License

MUTLU Y. G., Yıgıt Kaya S., MARAL S., MELEK E., BAŞLAR Z., KAYNAR L., ...More

Frontiers in Immunology, vol.14, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 14
  • Publication Date: 2023
  • Doi Number: 10.3389/fimmu.2023.1276295
  • Journal Name: Frontiers in Immunology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Directory of Open Access Journals
  • Keywords: BCMA, bispecific Ab, CNS involvement, Elranatamab, multiple myeloma
  • Open Archive Collection: AVESIS Open Access Collection
  • Istanbul University-Cerrahpasa Affiliated: Yes

Abstract

Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor T cells (CAR-T), have shown remarkable success in treating MM, but their efficacy in CNS involvement remains unclear. Elranatamab, a humanized bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3-expressing T cells, has demonstrated promising results in relapsed refractory MM. However, its efficacy in treating CNS-MM has not been reported. We present a case of a 37-year-old male MM patient with CNS involvement who has been successfully treated with Elranatamab.